Niktimvo FDA Approval History
FDA Approved: Yes (First approved August 14, 2024)
Brand name: Niktimvo
Generic name: axatilimab-csfr
Dosage form: Injection
Company: Incyte and Syndax Pharmaceuticals
Treatment for: Graft-versus-host disease
Niktimvo (axatilimab-csfr) is a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody used for the treatment of chronic graft-versus-host disease.
- Niktimvo is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.
Development timeline for Niktimvo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
